Dublin, September 28, 2020 (GLOBE NEWSWIRE) – ResearchAndMarkets. com has published a new article on the vaccine industry “Johnson & Johnson enters final phase of vaccine trial with 60,000 volunteers” Johnson & Johnson has verified the final phase of your COVID-19 vaccine candidate. The corporation will verify the vaccine with 60,000 volunteers around the world, adding participants from the United States, South Africa, Brazil, Argentina, Colombia and Chile. Johnson & Johnson’s vaccine joins applicants developed through Moderna, Pfizer and BioNTech, AstraZeneca and the University of Oxford to begin the latest level of development. The company has committed to making 1 billion doses of the non-beneficial vaccine. lucrative if proven effective. Unlike other vaccine applicants who require at least two doses, the J&J candidate asks for only one dose. It also does not require freezing and can remain viable in its liquid form for several months. If the Phase 3 trial is successful, either point can have vital practical benefits for mass immunization programs. For the full article and a list of similar reports in the market, stop at “Johnson & Johnson Enters Final Phase of 60,000 Volunteer Vaccine Trial”
About ResearchAndMarkets. com ResearchAndMarkets. com is the world’s leading source for market research reports and foreign market insight. We provide you with the latest knowledge on foreign and regional market places, key industries, the most sensible companies, new products and the latest trends.
Research and Markets also offers custom studies that offer specific, comprehensive and personalized studies.